Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Breast Cancer

  Free Subscription


08.06.2026

1 AJR Am J Roentgenol
2 Am J Epidemiol
3 Ann Oncol
2 Ann Surg Oncol
3 BMC Cancer
2 Br J Cancer
1 Breast Cancer
1 Breast Cancer (Auckl)
3 Breast Cancer (Dove Med Press)
1 Breast Cancer Res
6 Breast Cancer Res Treat
1 Breast J
2 Cancer
2 Cancer Lett
1 Carcinogenesis
1 Clin Breast Cancer
1 Clin Cancer Res
2 Clin Exp Metastasis
1 Eur Radiol
1 Gene
1 Int J Cancer
1 J Clin Oncol
1 Lancet Oncol
1 N Engl J Med
4 NPJ Breast Cancer
1 Oncogene
1 Oncology
1 PLoS Genet
10 PLoS One
1 Radiology


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. O'BRIEN SR
    Current and Emerging Quantitative Imaging Biomarkers in Breast Cancer.
    AJR Am J Roentgenol. 2026 Jun 3. doi: 10.2214/AJR.26.35291.
    PubMed        


    Am J Epidemiol

  2. FEI K, Teasdale CA, Terry MB, Schooling CM, et al
    Possible selection bias in Mendelian randomization studies: effect of body mass index on breast cancer as an example.
    Am J Epidemiol. 2026 Jun 4:kwag125. doi: 10.1093.
    PubMed         Abstract available

  3. GUPTA A, Osazuwa-Peters OL, Thoumi A, Quezada-Pinedo HG, et al
    Association of cultural racism with breast cancer survival among United States adults, 2018-2020.
    Am J Epidemiol. 2026 Jun 4:kwag126. doi: 10.1093.
    PubMed         Abstract available


    Ann Oncol

  4. DE AZAMBUJA E, Barrios CH, Bartsch R, Curigliano G, et al
    Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up(dagger).
    Ann Oncol. 2026 Dec 31:S0923-7534(26)00902-6. doi: 10.1016/j.annonc.2026.
    PubMed        

  5. KIM GM, Jung KH, Jeung HC, Lee J, et al
    A Randomized Phase III Trial of Anthracyclines Followed by Taxane versus Taxane Plus Carboplatin as (Neo)Adjuvant Therapy in Patients with Triple-Negative Breast Cancer: KCSG BR 15-1 PEARLY Trial.
    Ann Oncol. 2026 May 30:S0923-7534(26)00887-2. doi: 10.1016/j.annonc.2026.
    PubMed         Abstract available

  6. FRANCIS PA, Pagani O, Fleming GF, Walley BA, et al
    Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.
    Ann Oncol. 2026 Jun 1:S0923-7534(26)00888-4. doi: 10.1016/j.annonc.2026.
    PubMed         Abstract available


    Ann Surg Oncol

  7. HAGER MG, Hoskin TL, Ruddy KJ, Boughey JC, et al
    ASO Visual Abstract: Utility of 21-Gene Recurrence Score in Male Breast Cancer.
    Ann Surg Oncol. 2026 Jun 4. doi: 10.1245/s10434-026-19868.
    PubMed        

  8. LI K, Zhang Y, Liu Z, Wang S, et al
    ASO Visual Abstract: Global Inequalities in Female Breast Cancer Burden by Decomposition and Age-Period-Cohort Analysis, 1990-2021.
    Ann Surg Oncol. 2026 May 30. doi: 10.1245/s10434-026-19883.
    PubMed        


    BMC Cancer

  9. RADY RAZ N, Nafissi N, Babaee E, Fadavi P, et al
    Breast cancer survival prediction using machine learning and multimodal data for personalized care plan.
    BMC Cancer. 2026 Jun 1. doi: 10.1186/s12885-026-16283.
    PubMed         Abstract available

  10. MA X, Liu X, Ren J, Wang M, et al
    Factors influencing the impact of financial toxicity on the quality of life of breast cancer patients after mastectomies.
    BMC Cancer. 2026 Jun 4. doi: 10.1186/s12885-026-16259.
    PubMed         Abstract available

  11. LIU S, Liu J, Li D, Mo Q, et al
    Development and external validation of multiple machine learning-based models for breast cancer-specific survival prediction in postoperative patients with invasive breast cancer: a study based on the SEER database and an external cohort.
    BMC Cancer. 2026 May 30. doi: 10.1186/s12885-026-16166.
    PubMed         Abstract available


    Br J Cancer

  12. BOJESEN SE
    Risk-based breast cancer screening.
    Br J Cancer. 2026 Jun 3. doi: 10.1038/s41416-026-03489.
    PubMed        

  13. MICHAEL A, Huynh J, Sutton K, Chow MC, et al
    The utility of electronic frailty index in cancer patients undergoing chemotherapy.
    Br J Cancer. 2026;134:1793-1800.
    PubMed         Abstract available


    Breast Cancer

  14. MOUSAVIAN S, Sajjadi S, Khoroushi F, Ravanshad S, et al
    Charcoal localization of metastatic axillary lymphadenopathy in breast cancer patients: concordance with sentinel lymph node biopsy.
    Breast Cancer. 2026 Jun 3. doi: 10.1007/s12282-026-01877.
    PubMed         Abstract available


    Breast Cancer (Auckl)

  15. ABASS ELTAIB AHMED H, Gorish BMT, Mahjaf GM, Abdelmula WIY, et al
    Low Frequency of Pathogenic Variants in BRCA1 Exons 11/20 and BRCA2 Exon 11 Suggests Divergent Mutational Hotspots in Sudanese Breast Cancer Patients: A Case-Control Study.
    Breast Cancer (Auckl). 2026;20:11782234261455512.
    PubMed         Abstract available


    Breast Cancer (Dove Med Press)

  16. KULTUROGLU MO, Dogan L, Gulcelik MA
    Postoperative Complications Following Neoadjuvant Therapy Across Different Oncoplastic Breast Surgery Techniques: A Retrospective Comparative Study in Breast Cancer Patients.
    Breast Cancer (Dove Med Press). 2026;18:607172.
    PubMed         Abstract available

  17. KULLAB S, Refae A, Altwairgi A, Abusanad A, et al
    Management of HER2+ Breast Cancer with and without Brain Metastases in Saudi Arabia: Literature Insights and an Expert Survey of Current Practices.
    Breast Cancer (Dove Med Press). 2026;18:599184.
    PubMed         Abstract available

  18. LIU J, Zhang X
    Artificial Intelligence-Driven Quantitative HER2 Scoring and Spatial Bystander Effect Modeling for ADC Response Stratification in HER2-Low Breast Cancer.
    Breast Cancer (Dove Med Press). 2026;18:605985.
    PubMed         Abstract available


    Breast Cancer Res

  19. MONTOYO-PUJOL YG, Martinez-Peinado P, Pascual-Garcia S, Ortuno-Miquel S, et al
    A systemic immune signature stratifies early-stage breast cancer patients and reveals soluble IL-2RA and PD-1 as potential independent prognostic biomarkers.
    Breast Cancer Res. 2026 Jun 4. doi: 10.1186/s13058-026-02319.
    PubMed         Abstract available


    Breast Cancer Res Treat

  20. LEE KL, Yam C, Zhao L, Bassett RL, et al
    Non-BRCA germline pathogenic variants and response to neoadjuvant systemic therapy in triple-negative breast cancer patients enrolled in a prospective clinical trial.
    Breast Cancer Res Treat. 2026;217:39.
    PubMed         Abstract available

  21. BYEMERWA J, Neish D, Olunuga E, Osazuwa-Peters O, et al
    Association of cumulative lifetime estrogen exposure and reproductive factors with breast cancer molecular subtype among Nigerian women in the MEND study.
    Breast Cancer Res Treat. 2026;217:40.
    PubMed         Abstract available

  22. VUOTI S, Saari M, Lahti J, Narasimha K, et al
    Association of baseline tumor-infiltrating lymphocytes and cell-cycle regulation markers on prognosis and mortality in patients with advanced breast cancer according to tumor characteristics and treatment type: an observational study.
    Breast Cancer Res Treat. 2026;217:41.
    PubMed         Abstract available

  23. GONG CL, Chavez-MacGregor M, Xu X, Park L, et al
    The value of innovation in breast cancer treatment: real option value of olaparib for first-line treatment of gBRCA-mutated HER2 negative metastatic breast cancer.
    Breast Cancer Res Treat. 2026;217:42.
    PubMed         Abstract available

  24. XIA K, Tang N, Li D, Wang L, et al
    Retrospective study on regional nodal irradiation after omission of axillary lymph node dissection in sentinel lymph node-positive breast cancer: a propensity score matching analysis.
    Breast Cancer Res Treat. 2026;217:43.
    PubMed         Abstract available

  25. BARJIJ I, Naciri S, Lkhoyaali S, Kharmoum S, et al
    Post-neoadjuvant and peri-operative ctDNA-defined minimal residual disease in triple-negative breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2026;217:45.
    PubMed         Abstract available


    Breast J

  26. LESER C, Eisl R, Dorffner G, Kabashi F, et al
    Expert Opinions on Postoperative Complications in Breast Cancer Surgery After Neoadjuvant Chemotherapy: A Descriptive Study Through Structured Interviews With Surgeons in Austria.
    Breast J. 2026;2026:e6589301.
    PubMed         Abstract available


    Cancer

  27. SAKACH EA, Meisel JL, McArthur HL
    Antibody-drug conjugates in breast cancer.
    Cancer. 2026;132 Suppl 1:e70420.
    PubMed         Abstract available

  28. BALLINGER TJ, Zhao F, Jiang G, Shen F, et al
    Impact of patient-reported taxane-induced peripheral neuropathy on dose reductions or worsening quality of life in Black women with breast cancer: Analysis from ECOG-ACRIN EAZ171.
    Cancer. 2026;132:e70466.
    PubMed         Abstract available


    Cancer Lett

  29. ROY A, Ghosh A, Bhoumick A, Paul S, et al
    Thrombin-PAR1 signaling regulates Topoisomerase 1 activity to bridge inflammation and breast cancer progression.
    Cancer Lett. 2026;655:218646.
    PubMed         Abstract available

  30. ZHAO Z, Zheng ZY, Lei JT, Baik MJ, et al
    NF1 loss in estrogen receptor-positive breast cancer induces osteoclast formation and immunosuppression to promote bone metastasis.
    Cancer Lett. 2026;655:218636.
    PubMed         Abstract available


    Carcinogenesis

  31. YOU S, Li C, Sun W, Wang X, et al
    MEK/ERK/RSK2 positive feedback loop modulates EMT to promote migration and invasion of triple-negative breast cancer through regulating GALNT5 mRNA stability.
    Carcinogenesis. 2026 Jun 3:bgag038. doi: 10.1093.
    PubMed         Abstract available


    Clin Breast Cancer

  32. WOODSON AH, Al-Awadhi A, Corredor J, Casey J, et al
    Clinical Characteristics and Cancer Histories Among Breast Cancer Patients With Li-Fraumeni Syndrome From a Single Institution.
    Clin Breast Cancer. 2026;26:83-88.
    PubMed         Abstract available


    Clin Cancer Res

  33. FUKUMURA K, Jiang P, Yeboa DN, Singareeka Raghavendra A, et al
    Ionizing radiation enhances prognostically significant cellular immunity programs in the brain metastasis microenvironment.
    Clin Cancer Res. 2026 Mar 12. doi: 10.1158/1078-0432.CCR-25-3525.
    PubMed         Abstract available


    Clin Exp Metastasis

  34. PRICE ML, Zhou J, Le Maitre CL, Quayle LA, et al
    Mechanisms of breast cancer dormancy in bone metastasis.
    Clin Exp Metastasis. 2026;43:31.
    PubMed         Abstract available

  35. SPARTZ A, Schmidt S, Mohamed F, Troness B, et al
    Modeling the role of urokinase-type plasminogen activator, uPA, and circulating cancer-associated fibroblasts (cCAFs) in breast cancer cell extravasation.
    Clin Exp Metastasis. 2026;43:30.
    PubMed         Abstract available


    Eur Radiol

  36. HAN L, Jia N, Wang H, Zhang W, et al
    Combining Node-RADS with ADC can improve diagnostic performance for lymph node metastasis in breast cancer.
    Eur Radiol. 2026 Jun 3. doi: 10.1007/s00330-026-12649.
    PubMed         Abstract available


    Gene

  37. WANG J, Tian Y
    Circular RNA-centered regulatory networks in breast cancer: From ceRNA crosstalk to immune microenvironment reprogramming.
    Gene. 2026 May 29:150236. doi: 10.1016/j.gene.2026.150236.
    PubMed         Abstract available


    Int J Cancer

  38. MEIJER J, Hermanns N, Bijlsma R, Blommestein HM, et al
    Impact of Reimbursement on the Utilisation of Gene Expression Profiles and Chemotherapy Decision-Making in Dutch Breast Cancer Patients: A Population-Based Study.
    Int J Cancer. 2026 Jun 4. doi: 10.1002/ijc.70571.
    PubMed         Abstract available


    J Clin Oncol

  39. HURVITZ SA, Layman RM, Curigliano G, Andre F, et al
    Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.
    J Clin Oncol. 2026 Jun 4:JCO2601302. doi: 10.1200/JCO-26-01302.
    PubMed        


    Lancet Oncol

  40. KIRBY AM, Hatton NL, Hansen VN, Thomas M, et al
    Real-world heart and lung doses from 30 000 National Health Service radiotherapy treatment plans in England: a national audit of breast radiotherapy practice.
    Lancet Oncol. 2026;27:751-760.
    PubMed         Abstract available


    N Engl J Med

  41. SHARIFI N
    Fasting, Glucocorticoids, and Breast Cancer.
    N Engl J Med. 2026;394:2163-2165.
    PubMed        


    NPJ Breast Cancer

  42. TAVARES MC, Balint FC, Barroso-Sousa R, Testa L, et al
    Neoadjuvant pembrolizumab plus chemotherapy in germline BRCA-mutated early triple-negative breast cancer: a multicenter real-world cohort.
    NPJ Breast Cancer. 2026 Jun 2. doi: 10.1038/s41523-026-00966.
    PubMed         Abstract available

  43. KWAKKENBOS K, van den Ende NS, Heemskerk-Gerritsen BAM, Veenland JF, et al
    Machine learning-based identification of high-risk triple-negative breast cancer patients despite pathological complete response after neoadjuvant chemotherapy.
    NPJ Breast Cancer. 2026 Jun 2. doi: 10.1038/s41523-026-00979.
    PubMed         Abstract available

  44. ZHU S, Jin Y, Hu C, Fan Y, et al
    Diagnostic Performance of (68)Ga-FAPI PET/CT Versus (18)F-FDG PET/CT in Evaluating Neoadjuvant Therapy Pathological Response in Breast Cancer.
    NPJ Breast Cancer. 2026 Jun 2. doi: 10.1038/s41523-026-00983.
    PubMed         Abstract available

  45. THANGAVEL H, Dhanyalayam D, Lizardo K, Bansal S, et al
    Cancer-associated adipomes promote invadopodia formation and enhance metastatic potential in triple-negative breast cancer.
    NPJ Breast Cancer. 2026 Jun 3. doi: 10.1038/s41523-026-00985.
    PubMed         Abstract available


    Oncogene

  46. SUN Y, Feng R, Zhou X, Xu W, et al
    TIA1 depletion enhances CLSTN1 exon 11 inclusion to facilitate Epithelial-to-Mesenchymal transition and breast cancer metastasis.
    Oncogene. 2026 Jun 1. doi: 10.1038/s41388-026-03831.
    PubMed         Abstract available


    Oncology

  47. UMEHARA K, Saito Y, Takada S, Yamamoto M, et al
    Impact of Abemaciclib-Induced Serum Creatinine Elevation on Dose Adjustment of Concomitant Medications.
    Oncology. 2026;104:655-662.
    PubMed         Abstract available


    PLoS Genet

  48. ZHANG H, He K, Tsoi LC, Zhou X, et al
    mFABIO: An integrative multi-tissue TWAS fine-mapping approach to prioritize potentially causal genes and tissues underlying binary traits.
    PLoS Genet. 2026;22:e1012157.
    PubMed         Abstract available


    PLoS One

  49. SCHOUTEN AEM, Frederix GWJ, Stuiver MM, Fischer F, et al
    Choice and impact of EQ-5D-5L value set in cost-utility analyses alongside multinational trials: Insights from PREFERABLE-EFFECT and CONVINCE.
    PLoS One. 2026;21:e0350019.
    PubMed         Abstract available

  50. NARASIMHAN RM, Saini AS, Samimi K, Ogobuiro I, et al
    Postmastectomy radiotherapy in pN1 breast cancer: Survival outcomes and prognostic factors from a single-institution cohort.
    PLoS One. 2026;21:e0341754.
    PubMed         Abstract available

  51. SARKER H, Farid FB, Kamrun M, Masud E, et al
    Multi-omics and pan-cancer analysis revealed common molecular signatures to disclose multitargeted anticancer agents through network pharmacology approach.
    PLoS One. 2026;21:e0350614.
    PubMed         Abstract available

  52. ARAFAT HM, Tengku Din TADA, Shafii N, Muhamad R, et al
    Interplay of the IGFBP-3 polymorphism and serum levels of IGF-1/IGFBP-3 with hormone receptor subtypes in patients with breast cancer among Palestinian women.
    PLoS One. 2026;21:e0350553.
    PubMed         Abstract available

  53. MANKELOW KA, O'Connor S, Santin O, Blackburn NE, et al
    Digital exercise interventions to improve physical functioning of people with breast cancer: Protocol for a scoping review.
    PLoS One. 2026;21:e0350300.
    PubMed         Abstract available

  54. YANG W
    Tumor hypoxia is associated with global copy-number alteration burden and subtype-dependent overall survival in breast cancer: Evidence from TCGA and METABRIC.
    PLoS One. 2026;21:e0350829.
    PubMed         Abstract available

  55. ZHENG L, Li W, Wang B, Wu T, et al
    Identification of potential key genes that respond to capsaicin treatment in ER-positive breast cancer: An integrated analysis.
    PLoS One. 2026;21:e0350841.
    PubMed         Abstract available

  56. SOLIMAN SSM, Alhamidi TB, Abdin S, Almehdi AM, et al
    Correction: Effective targeting of breast cancer cells (MCF7) via novel biogenic synthesis of gold nanoparticles using cancer-derived metabolites.
    PLoS One. 2026;21:e0350791.
    PubMed         Abstract available

  57. AL-DAMOOK N, Sakkal M, Khair M, Mousa WK, et al
    Mapping metabolic reprogramming in lung and breast cancer through integrative bioinformatics.
    PLoS One. 2026;21:e0350628.
    PubMed         Abstract available

  58. OMORI K, Furukawa K, Usubuchi M, Hamada T, et al
    A multicenter, randomized, parallel-group confirmatory study protocol to evaluate the efficacy of Soft Protector CPC, a novel oral mucosal protectant, in preventing oral mucositis and alleviating pain in patients with breast cancer.
    PLoS One. 2026;21:e0350803.
    PubMed         Abstract available


    Radiology

  59. BAHL M, Mercaldo S, Lamb LR
    Impact of AI-based Slab Reconstruction Technology on the Diagnostic Accuracy of Screening Digital Breast Tomosynthesis.
    Radiology. 2026;319:e252685.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum